On July 21, 2022 GlyTherix reported the successful completion of its high-yield GMP-grade stable cell line development program for its proprietary antibody Miltuximab in partnership with international biologics manufacturer GenScript ProBio (New Jersey, USA) (Press release, Glytherix, JUL 21, 2022, View Source [SID1234616831]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Establishing a stable, high-yield cell line suitable for commercial production of clinical-grade monoclonal antibody is a critical milestone for the Company. The Chinese Hamster Ovary (CHO) cell clones selected for Miltuximab cell banking have reached titres of above 8g/L. Work is now continuing on the process development program for scale-up of Miltuximab manufacturing at 100L-bioreactor scale for the Company’s upcoming Australian Phase I trial.
Miltuximab will be used in a Phase Ib trial as an antibody theranostic. Antibody labelled with 89-Zirconium will be used as an imaging agent to select patients showing tumor targeting. This will be followed by patients being offered Miltuximab labelled with 177-Lutetium as a therapeutic dose.
To find out more about GlyTherix’s technology and clinical program, visit www.glytherix.com
GlyTherix is seeking investors who would like to participate in the company’s Series A funding round.
This project received grant funding from the Australian Government.